Biotech VC dips in 3Q, but 2014 on track to beat 2013

US venture capital investment in private biotechnology companies dipped to $1.05bn in the third quarter from $1.84bn in the second quarter, but venture funding in 2014 remains on track to beat the 2013 total and may exceed $5bn for the year – a total that hasn't been reached since 2008.

US venture capital investment in private biotechnology companies dipped to $1.05bn in the third quarter from $1.84bn in the second quarter, but venture funding in 2014 remains on track to beat the 2013 total and may exceed $5bn for the year – a total that hasn't been reached since 2008.

Venture capital funds invested nearly $4bn in biotech firms during the first nine months of 2014, according to the quarterly...

Welcome to Scrip

Create an account to read this article

More from Anticancer

ESMO 25: Tolerability Raised As Exelixis STELLAR-303 Study Still Needs To Mature

 

Exelixis’s novel kinase inhibitor zanzalintinib has shown promise in a metastatic colorectal cancer population but some experts want to see more data before passing judgement on whether it can become a new chemotherapy-free treatment option for these patients.

Ipsen Boosts Cancer Pipeline With ImCheck Buy

 
• By 

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By 

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

More from Therapy Areas

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

Neuphoria To Look At Strategic Options After BNC210 Fails In Social Anxiety

 

Neuphoria said that its Phase III trial of BNC210 in social anxiety disorder did not meet the primary or secondary endpoints, but its PTSD program will continue.

ESMO 25: Ovarian Cancer Data Validates Tubulis ADC Platform

 
• By 

Positive first-in-human data for TUB-040 represent "a momentous milestone" for the German biotech, according to its CEO Dominik Schumacher.